[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Philip H. Coelho net worth and biography

Philip Coelho Biography and Net Worth

Director of Catalyst Pharmaceuticals

Philip H. Coelho, Founder and Chief Technology Officer (CTO)of Thermogenesis Corp., is an engineer and inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He holds more than 40 U.S. patents related to cell selection, cell cryopreservation, cell washing, automated cryogenic freezing and storage of cells and harvesting clotting proteins from blood. As Founder, Chairman and CEO of Thermogenesis Corp., Mr. Coelho developed the Thermoline ultra rapid blood plasma freezer and thawer; the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood; the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood; and the AutoXpress System, which automates harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive and AutoXpress Systems have established the highest quality GMP standards in cord blood processing and banking worldwide. Mr. Coelho retired from Thermogenesis Corp in August 2007. In 2009, Mr. Coelho co-founded SynGen Inc., and began the development of programmable systems that improve the speed and efficiency of the isolation and capture of purified stem, progenitor and immune cells residing within peripheral or placental/cord blood, bone marrow aspirate and leukapheresis. In July 2017, SynGen merged with Thermogenesis Corp, now a subsidiary of Cesca Therapeutics, and Mr. Coelho accepted the position of CTO in the combined company. He is now leading the development of CAR-TXpress, an automated method of manufacturing therapeutic doses of CAR T-cells in a functionally closed cell processing system. Mr. Coelho has been a member of the Catalyst Board of Directors since October 2002.

What is Philip H. Coelho's net worth?: The estimated net worth of Philip H. Coelho is at least $3.24 million as of November 23rd, 2022. Mr. Coelho owns 149,553 shares of Catalyst Pharmaceuticals stock worth more than $3,243,805 as of November 15th. This net worth estimate does not reflect any other assets that Mr. Coelho may own. Learn More about Philip H. Coelho's net worth.
How do I contact Philip H. Coelho?: The corporate mailing address for Mr. Coelho and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Philip H. Coelho's contact information.
Has Philip H. Coelho been buying or selling shares of Catalyst Pharmaceuticals?: Philip H. Coelho has not been actively trading shares of Catalyst Pharmaceuticals during the past quarter. Most recently, Philip H. Coelho sold 9,999 shares of the business's stock in a transaction on Wednesday, November 23rd. The shares were sold at an average price of $17.45, for a transaction totalling $174,482.55. Following the completion of the sale, the director now directly owns 149,553 shares of the company's stock, valued at $2,609,699.85. Learn More on Philip H. Coelho's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 551,255 shares worth more than $9,231,148.44. The most recent insider tranaction occured on August, 21st when Director David S Tierney sold 15,000 shares worth more than $301,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 8/21/2024.

Philip H. Coelho Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/23/2022	Sell	9,999	$17.45	$174,482.55	149,553
11/21/2022	Sell	70,000	$15.23	$1,066,100.00	179,553
8/25/2021	Sell	9,498	$5.56	$52,808.88	233,427
6/17/2016	Buy	15,000	$0.76	$11,400.00	159,987
3/17/2016	Buy	10,000	$1.06	$10,600.00	158,287
11/15/2012	Buy	24,000	$0.41	$9,840.00

Philip H. Coelho Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.69

$21.53

$22.73

50 Day Range

MA: $20.97

$19.37

$23.93

2 Week Range

Now: $21.69

$13.00

$24.27

Volume

1,226,194 shs

Average Volume

1,194,411 shs

Market Capitalization

$2.59 billion

P/E Ratio

18.38

Dividend Yield

N/A

Beta

0.75